Grade B
Rct
Senolytics Dasatinib+Quercetin: First Human Trial Results
First-in-human trial of senolytic combination dasatinib plus quercetin for clearing senescent cells in idiopathic pulmonary fibrosis patients.
Published 2024
18 views
[STUDY DETAILS]
- Study Type
- Rct
- Quality Grade
- B
- Publication Year
- 2024
- Category
- Longevity & Aging
Summary
Pilot study (n=14) found 3 doses of D+Q over 3 weeks improved 6-minute walk distance by 21 meters and reduced senescence markers SASP factors by 25-40% in IPF patients.
Key Findings
1. Walking distance +21 meters
2. SASP markers reduced 25-40%
3. Intermittent dosing well-tolerated
4. Effects persisted 2 weeks post-treatment